| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Friday, October 20, 2017 Merck & Co. plans to jettison three U.S. sales teams and 1,800 associated staffers while creating a new, 960-employee chronic care force. |
|
|
Top Stories Of The Week Friday, October 20, 2017 Celgene has scrapped a phase 3 trial of inflammatory bowel disease drug GED-0301 after it failed to clear an interim futility review. The decision leaves Celgene facing the prospect of canning a drug it paid $710 million upfront for in 2014. Friday, October 20, 2017 GlaxoSmithKline has the official go-ahead for its next big launch. Late Friday, the FDA approved the company's new shingles vaccine, Shingrix, setting up a market duel with blockbuster implications between GSK and Merck. Tuesday, October 24, 2017 In new phase 2 data published today, Gilead says a higher dose of its NASH drug saw statistically significant reductions in liver fat, although a lower dose missed the mark. Tuesday, October 24, 2017 Defying critics in Congress and elsewhere, Celgene hiked the list prices of key cancer medications Revlimid and Pomalyst by 9% this month, taking their cumulative increases for the year into ranges that many Big Pharma peers have pledged to avoid. Friday, October 20, 2017 Earlier this month, Johnson & Johnson announced it would stop making and selling its Animas insulin pumps in the U.S. and Canada. Now, a WARN notice shows, the company will lay off 297 employees in Pennsylvania. Wednesday, October 25, 2017 GlaxoSmithKline said Wednesday that it's looking hard at Pfizer’s up-for-sale OTC unit—but that was bad news to analysts worried about the fate of the company’s dividend. Sunday, October 22, 2017 Immunotherapy is promising, but identifying tumor-specific antigens for immuno-oncology treatments to target has proven challenging. Now, using a gene circuit encoded in DNA, scientists at MIT have found a way to identify cancer cells more accurately and stimulate the immune system more effectively. Friday, October 20, 2017 Still struggling to turn its manufacturing around, Dr. Reddy's is recalling 569,000 store-brand famotidine tablets in the U.S., thanks to failed tests for impurities and degradation. It's the India-based company's second recall of the same medication since last July. Wednesday, October 25, 2017 Major CRO Parexel has teamed up with Microsoft to create a new cloud technology alliance aimed at speeding up drug research. The pair said they are hoping to “drive digital transformation” of biopharma through the pact, which will combine Parexel’s drug development work with Microsoft’s cloud computing tech Azure. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Veeva Systems CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. Sponsored by: Veeva Systems The 2017 Unified Clinical Operations Survey finds that 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. |
|
